Received: from GVXPR02MB12202.eurprd02.prod.outlook.com (2603:10a6:150:318::18) by DU4PR02MB11430.eurprd02.prod.outlook.com (2603:10a6:10:5d3::9) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9913.11; Wed, 13 May 2026 12:49:50 +0000 Received: from DU4PR02MB11430.eurprd02.prod.outlook.com (2603:10a6:10:5d3::9) by DB9PR02MB7817.eurprd02.prod.outlook.com with HTTPS; Wed, 13 May 2026 12:49:51 +0000 Received: from GVXPR02MB12202.eurprd02.prod.outlook.com ([fe80::7e68:6b0b:67d4:d05f]) by GVXPR02MB12202.eurprd02.prod.outlook.com ([fe80::7e68:6b0b:67d4:d05f%2]) with mapi id 15.20.9891.021; Wed, 13 May 2026 12:49:50 +0000 From: "Andrus Varki - RA" To: "Info - SOM" Cc: =?utf-8?Q?K=C3=A4rolin_Jenas_-_RA?= References: <0b1142f2de5b4ee9b77a206ee9671966@ravimiamet.ee> In-Reply-To: <0b1142f2de5b4ee9b77a206ee9671966@ravimiamet.ee> Subject: =?utf-8?Q?Ed:_Eeln=C3=B5u_edastamine_koosk=C3=B5last?= =?utf-8?Q?amiseks_ja_arvamuse_avaldamiseks?= Date: Wed, 13 May 2026 15:49:49 +0300 Keywords: liivia Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_0317_01DCE2F1.18465350" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQIOkpl4/ke9+WNmGnvinYgaN9pG2wEidV1A Authentication-Results: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; x-ms-traffictypediagnostic: GVXPR02MB12202:EE_|DU4PR02MB11430:EE_|DB9PR02MB7817:EE_ X-MS-Office365-Filtering-Correlation-Id: a4e360a1-08d7-46d1-6efe-08deb0ee1ee6 X-MS-Exchange-AtpMessageProperties: SA X-MS-Exchange-Transport-CrossTenantHeadersStamped: DU4PR02MB11430 X-MS-Exchange-Organization-ExpirationStartTime: 13 May 2026 12:49:50.4253 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: a4e360a1-08d7-46d1-6efe-08deb0ee1ee6 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-Exchange-Organization-AuthAs: Internal X-MS-Exchange-Organization-AuthSource: GVXPR02MB12202.eurprd02.prod.outlook.com X-MS-Exchange-Organization-SCL: 1 X-MS-PublicTrafficType: Email X-Microsoft-Antispam: BCL:0;ARA:13230040|31052699007|39142699007|366016|55112099003|13003099007|8096899003|56012099003|18002099003|22082099003|11063799003|41050700001; X-Forefront-Antispam-Report: CIP:255.255.255.255;CTRY:;LANG:ja;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GVXPR02MB12202.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(31052699007)(39142699007)(366016)(55112099003)(13003099007)(8096899003)(56012099003)(18002099003)(22082099003)(11063799003)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 13 May 2026 12:49:49.9977 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: a4e360a1-08d7-46d1-6efe-08deb0ee1ee6 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-AuthSource: GVXPR02MB12202.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-FromEntityHeader: Hosted X-MS-Exchange-Transport-EndToEndLatency: 00:00:01.5774329 X-MS-Exchange-Processed-By-BccFoldering: 15.20.9913.007 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 Content-Language: et x-ms-exchange-organization-originalclientipaddress: 45.156.32.7 x-ms-exchange-organization-originalserveripaddress: 2603:10a6:150:318::18 X-OlkEid: 000000004943FF4B2AE9BB419B4D9712F9BA8BFE070034AD76187591974DBF6C4F76951C873A010002000000000068E7CFE0145B3B499213B01F169BEE390000000006DC000005E9D0E1FDAB9145A2B14ED460A71EB1 X-MS-Has-Attach: X-MS-TNEF-Correlator: acceptlanguage: et-EE, en-US X-CodeTwoProcessed: true X-MS-Exchange-Organization-AuthMechanism: 04 msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-05-13T12:49:49.701Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; X-MS-Exchange-Organization-ModifySensitivityLabel: 00000000-0000-0000-0000-000000000000;defa4170-0d19-0005-0004-bc88714345d2 x-codetwo-clientsignature-inserted: true X-MS-Exchange-CrossTenant-MailboxType: HOSTED X-MS-Exchange-CrossTenant-UserPrincipalName: oiCr3q/wb/EHas+Lu9JtzPoXND+bP9yqYMkoqdA0q+L0vjiKgnZH1TfZ0R8k+O25uYoD2pUuhJRMfQQ4dSKfuTDn4u2Lf0V3ERMrLPRoKJM= This is a multipart message in MIME format. ------=_NextPart_000_0317_01DCE2F1.18465350 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit Teie:    27.04.2026 nr 1.2-2/40-1 Meie:   13.05.2026 nr JUR-3/1493-2 Tere Edastame Ravimiameti ettepanekud sotsiaalministri määruse "Meditsiiniseadmete ja abivahendite andmekogu põhimäärus" eelnõule. Teeme ettepaneku täiendada eelnõu § 8 punkte 2 ja 4 järgmiselt: 2) seadmete levitaja või importija – § 7 lõike 1 punktides 1, 2 ja 3 nimetatud andmed; 4) hüvitatavate meditsiiniseadmete levitaja – § 7 lõike 1 punktides 1, 2, 3 ja 4 nimetatud andmed; Seadmete (k.a hüvitatavate meditsiiniseadmete) levitajal ja importijal tuleb samuti esitada § 7 lõike 1 punktis 1 nimetatud andmed ehk ettevõtja ja tema esindaja andmed. Eelnõu § 17 ja § 18 osas teeme ettepaneku sätestada määruse jõustumise ning määruse nr 80 kehtetuks tunnistamise ajaks 06. juuli 2026. Uue IT-lahenduse kasutuselevõtt on hetkel planeeritud 06. juuli 2026. Lugupidamisega Andrus Varki juhataja Õigusosakond Ravimiamet 737 4140 www.ravimiamet.ee Selles e-kirjas sisalduv teave (kaasa arvatud manused) on mõeldud ametialaseks kasutamiseks ning seda võivad kasutada vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, teavitage sellest koheselt saatjat ning kustutage e-kiri. This e-mail and any attachments transmitted may contain confidential and privileged information. If you are not the intended recipient, please notify the sender immediately by returning the e-mail and permanently deleting what you have received. Any dissemination or use of this information by a third person without permission is prohibited and may be illegal. ------=_NextPart_000_0317_01DCE2F1.18465350 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable
Teie:=E2=80=82=E2=80=82=E2=80=82=E2=80=8227.04.2026 nr 1.2-2/40-1
Meie:=E2=80=82=E2=80=82=E2=80=8213.05.2026 nr JUR-3/1493-2

Tere

Edastame Ravimiameti ettepanekud sotsiaalministri m=C3=A4=C3=A4ruse = "Meditsiiniseadmete ja abivahendite andmekogu = p=C3=B5him=C3=A4=C3=A4rus" eeln=C3=B5ule. 

Teeme ettepaneku t=C3=A4iendada eeln=C3=B5u =C2=A7 8 punkte 2 ja 4 = j=C3=A4rgmiselt: 
2) seadmete levitaja v=C3=B5i importija =E2=80=93 =C2=A7 7 l=C3=B5ike 1 = punktides 1, 2 ja 3 nimetatud andmed;
4) h=C3=BCvitatavate meditsiiniseadmete = levitaja =E2=80=93 =C2=A7 7 l=C3=B5ike 1 punktides = 1, 2, 3 ja 4 nimetatud andmed;

Seadmete (k.a h=C3=BCvitatavate meditsiiniseadmete) levitajal ja = importijal tuleb samuti esitada =C2=A7 7 l=C3=B5ike 1 punktis 1 = nimetatud andmed ehk ettev=C3=B5tja ja tema esindaja andmed. 

Eeln=C3=B5u =C2=A7 17 ja =C2=A7 18 osas teeme ettepaneku s=C3=A4testada = m=C3=A4=C3=A4ruse j=C3=B5ustumise ning m=C3=A4=C3=A4ruse nr 80 kehtetuks = tunnistamise ajaks 06. juuli 2026. Uue IT-lahenduse kasutuselev=C3=B5tt = on hetkel planeeritud 06. juuli 2026.

Lugupidamisega

Andrus Varki

juhataja

=C3=95igusosakond


Ravimiamet

737 4140

www.ravimiamet.ee


Selles e-kirjas sisalduv teave (kaasa arvatud manused) on = m=C3=B5eldud ametialaseks kasutamiseks ning seda v=C3=B5ivad kasutada = vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja = selgelt v=C3=A4ljendatud loata edasi saata ega mis tahes viisil = kolmandatele isikutele avaldada. Juhul, kui Te olete saanud = k=C3=A4esoleva e-kirja eksituse t=C3=B5ttu, teavitage sellest koheselt = saatjat ning kustutage e-kiri. 
This e-mail and any attachments transmitted may = contain confidential and privileged information. If you are not the = intended recipient, please notify the sender immediately by = returning the e-mail and permanently deleting what you have = received. Any dissemination or use of this information by a third person without permission is = prohibited and may be illegal. 



 

------=_NextPart_000_0317_01DCE2F1.18465350--